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Abstract. – Opioids are drugs of reference
for the treatment of moderate to severe pain.
Their proper use and a periodic assessment of
the patient are crucial to prevent misuse. A mul-
tidisciplinary group suggests strategies for all
stakeholders involved in the management of
pain and suggests the importance of the doctor-
patient relationship.
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Introduction
Appropriate Pain Management
The diagnosis and treatment of pain is a clini-
cal and ethical imperative, and access to con-
trolled drugs for medical purposes, particularly
pain medications, should be guaranteed to all pa-
tients in need1,2. Current clinical practice recom-
mendations indicate opioids as the gold standard
for treatment of moderate-to-severe acute and
chronic pain, according to the WHO analgesic
ladder and other international guidelines3-7. 
To establish an appropriate and personalized
plan of care, a general assessment of the patient
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with pain is crucial, thus permitting an appropri-
ate prescription of opioid medications. Accord-
ingly, periodic re-assessment and accurate moni-
toring are essential for the correct management
of pain pharmacotherapy (Table I).
As reported in the World Drug Report8, at the
international level availability of opioids for
medical purposes does not correlate with abuse,
misuse, or diversion2. Several countries with
very high per capita opioid-medication availabil-
ity do not show high levels of abuse. In contrast,
some countries with limited access to these med-
ications for medical purposes present a high level
of abuse and misuse. Financial, cultural and leg-
islative factors may interfere with the relation-
ship beyond the role attributed to availability in a
simplistic way.
The effectiveness of opioid medications in
controlling pain and inducing analgesia may be
associated, in a minority of cases, with addic-
tion, misuse and non-therapeutic use, particu-
larly in vulnerable individuals. However, ad-
diction is rare in patients with no previous his-
tory of addiction9. Using a structured evidence-
based review of 67 studies, Fishbain et al10. cal-
culated the abuse/addiction rate to be 3.3%.
When considering only patients with no history
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Assessment of physical, psychological, social/family existential suffering 
Assessment of background pain (and breakthrough pain in cancer patients)
Assessment of the causes of pain with a proper diagnosis (for example assessing neuropathic, nociceptive or mixed pain)
and evaluation of analgesic need 
Selection of drugs on the basis of the characteristics of pain 
Pharmacotherapy management (dose titration with immediate-release formulations to reach minimum effective dose
and/or maximum tolerated, switching of route/opioid when needed, dose adjustments for tolerance, hyperalgesia, or ad-
verse events) 
Periodic re-assessment of pain
Counseling and assessment of misuse risk (patient, family, caregiver)
Multidisciplinary health care pathway for uncontrolled pain
Table I. Systematic, accurate, and personalized management of people suffering with pain.
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dictive behavioural pattern characterized by the
compulsive cycle. Patients with unrelieved pain
may in fact become focused on obtaining med-
ications. For all these reasons, in patients with
chronic pain a periodic review of the strategy and
a detailed evaluation of behaviours are recom-
mended (Table II).
To better explain the uncommon risk of addic-
tion in patients with pain, the conditions to in-
duce addictive behaviour and opioid use disor-
ders should be considered extensively. Addiction
is not simply related to the exposure to opioid
medications, but to a complex series of social
and neurobiological factors inducing loss of con-
trol over drug use. The addicted patient is char-
acterized by compulsive use, craving, and contin-
ued use despite harmful consequences. The ther-
apeutic use of opioids in patients with pain is
usually not associated with any risk factor which
underlies the development of substance use dis-
orders in the clinical history. Furthermore, neuro-
biological data demonstrated that subjects suffer-
of abuse/addiction, the percentage of abuse/ad-
diction dropped to 0.2%10. Overall, these fig-
ures suggest a low risk of opioid abuse/addic-
tive behaviour in clinical practice. Existing evi-
dence and clinical experience suggest that in
appropriately-selected patients, opioids have a
low addictive potential and, in addition to their
primary analgesic action, they are able to re-
duce suffering, enhance functional activity lev-
el, and improve quality of life11. 
From a clinical perspective, the symptoms of
compulsive/addictive behaviour in patients with
pain should also be distinguished from those re-
lated to “pseudoaddiction”. The term “pseudoad-
diction” is used to describe a reversible condition
in patients with undertreated chronic pain show-
ing erratic behaviour that resolves once pain be-
comes adequately controlled12. To this end, prac-
titioners working in the pain management area
should also differentiate the effects of tolerance
in patients in need of higher dosage of opioid
medications to maintain analgesia from the ad-
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Appropriate use of opioids
Implement combination therapies with multiple drugs (aiming at opioid-sparing)
Reserve the higher doses and long-acting formulations for patients with persistent pain after titration
Prefer safe packages (e.g. child-proof packaging)
Prefer opioid with abuse-deterrent formulation or device should be preferred
Schedule frequent monitoring visits 
Avoid under treatment of chronic pain 
Discourage multiple prescriptions (centralize the prescription to the specialist or the GP who is in charge of the patient)
Avoid unecessary prescriptions 
Check drug adherence periodically
Share the therapy strategy with the patient (including the benefit/risk ratio)
Continuous counseling
Screening patients at potential risk with validated tools (comorbidity drug abuse, non-drug abuse conditions, psychiatric
conditions)
Discuss patients’ management with other specialists (pain specialist, addiction specialist, GPs)
Table II. Strategies to manage the opioid treatment.
ing for neuropathic chronic pain undergo a series
of neuro-plastic changes, which do not support
the reinforcing, rewarding effects of opiates and
potential abuse13. 
Although the prescription-drugs abuse epi-
demic in the United States14,15 has been interpret-
ed in different ways, the real nature of the phe-
nomenon remains unclear. A variety of factors,
typical of the normative, cultural and social con-
ditions in the US could have induced the over-
whelming rate of abuse that seems to be uncom-
mon16 and not expected in Europe and in Italy.
This has led many experts in the US to propose
strategies to reduce the risk of diversion17,18. To
enhance the rate of appropriate use of opioid
medications in patients requiring analgesia a
multimodal approach should be applied not only
by physicians, but also by other stakeholders
(Table III).
For a long time analgesic opioids have been
used in small amounts and only for terminal can-
cer patients with pain. With the recent approval
of the Italian law no. 38/2010, opioids have be-
come more readily available to patients needing
analgesia. Although the access modalities to drug
therapies in Italy is different from those applied
in other countries and opioid abuse remains a
rare event in patients with chronic pain9,18,19, the
strategies to avoid drugs abuse should be careful-
ly considered. Multimodal strategies should be
implemented and disseminated to reduce the po-
tential risk of misuse and abuse: in particular the
training of health professionals should provide
the necessary skill for the mitigation of abuse
and diversion. The use of opioids must be in full
compliance with the approved indications to
avoid misuse; however, the fear of abuse should
not discourage the appropriate use of these effec-
tive drugs in the control of pain. Opioid treat-
ment should not be denied in paediatric patients,
according to the WHO indications. In fact mor-
phine was recommended by WHO as second-line
treatment after paracetamol or ibuprofen for per-
sisting moderate to severe pain in children20. Ap-
propriate management of pain is also recom-
mended, both during and/or after treatments and
diagnostic procedures21. In both these settings
abuse and diversion are unlikely.
As a main element to avoid abuse and diver-
sion, particular emphasis should be given to the
concept of “therapeutic alliance” between the
healthcare professional and the patient22. An in-
dividualized approach, considering not only the
pain, but the entire person affected and his/her
own needs and expectations, would significantly
increase not only the benefits of pain pharma-
cotherapy and also decrease the risk of uncon-
trolled and abusive use. General practitioners
should be fully involved in the multidisciplinary
pathway of care in order to detect patients at risk
earlier, centralize and monitor prescriptions, pe-
riodically reassess the chronic pain situation and
involve patient and family in the management of
opioid therapy. In this setting, a validation tool to
4205
The prevention of analgesic opioids abuse: expert opinion
1. Health Authorities 
Mandatory training to physicians about the proper prescription of pain medications 
Public awareness campaigns on the proper use of pain medications 
Active surveillance of analgesic abuse
2. Scientific Societies
Guidelines to manage long-term opioid therapy
Validation of tools to assess the risk of drugs abuse 
Multidisciplinary training program (for specialists and GPs) 
3. Pharmacists
Surveillance of suspected abuse of opioid painkillers (multiple prescriptions, incorrect dosage)
Ensure the availability of all formulations of opioids (immediate, rapid or sustained-release)
Counseling on the correct dosage and storage
4. Nurses
Survey and counseling
Participation to the multidisciplinary risk assessment plan
5. Pharmaceutical companies
Implement child-proof packaging 
Implement abuse-deterrent formulations
Promote the approved indications and proper use
Active monitoring and assessment of safety profile and risk/benefit ratio
Table III. Multimodal strategies to manage the opioid risk.
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aid the early detection of patients at risk is also
crucial. Lastly, appropriate modalities should be
adopted to not deny the necessary opioid medica-
tions to patients at risk of abuse affected by se-
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